← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
The University Of Texas Southwestern Medical Center
$179,655,410
Total funding
227
Grants
Funding over time
peak $37.3M · FY2008–25$50M$37.5M$25M$12.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$130,211,142 · 195
NASA$41,078,425 · 22
DOE$7,578,541 · 7
USDA$787,302 · 3
By mechanism
—$179,655,410 · 227
Investigators at The University Of Texas Southwestern Medical Center
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
LUNG CANCER PATHOGENISIS AND HZE PARTICLE EXP$9,386,670
· FY2008 · National Aeronautics and Space Administration
GULF WAR ILLNESS RESEARCH PROGRAM$8,546,338
· FY2008 · Department of Defense
THE UT SOUTHWESTERN MEDICAL CENTER PROPOSAL FOCUSES ON THE DETERMINATION AND QUANTITATION OF RISK FACTORS FROM KEY GENETIC, EPIGENETIC AND CELLULAR F$7,601,898
· FY2014 · National Aeronautics and Space Administration
DEVELOPMENT IF INVIVO BIOMARKERS FOR PROGRESSIVE TAU PATHOLOGY AFTER TRAUMATIC BRAIN INJURY$2,945,851
· FY2013 · Department of the Army
ADVANCED MAGNETIC RESONANCE RESEARCH INSTRUMENT AT UT SOUTHWESTERN MEDICAL CENTER METROPLEX COMPLEX COMPREHENSIVE IMAGING CENTER$2,906,335
· FY2008 · Department of Energy
CARDIAC ATROPHY&DYSFUNCTION DURING&AFTER LONG DURATION SPACEFLIGHT$2,656,476
· FY2008 · National Aeronautics and Space Administration
NEW AWARD; TITLE: LOW DOSE IR ACTIVATION OF TGF-BETA 1-IGF-1-SCLU IN VIVO: MECHANISMS, FUNCTIONS OF A CHANGING MICROENVIRONMENT; PI: DAVID BOOTHMAN$2,574,931
· FY2009 · Department of Energy
OVERALL HYPOTHESIS.. LOW DOSE RADIATION INDUCES MOLECULAR MANIFESTATIONS OF A PRO INFLAMMATORY RESPONSE AS A FUNCTION OF RADIATION TYPE, RADIATION DO$2,478,052
· FY2016 · National Aeronautics and Space Administration
DNA DAMAGE RESPONSES INDUCED BY HZE PARTICLES IN HUMAN CELLS, RESEARCH OPPORTUNITIES FOR GROUND BASED RESEARCH IN SPACE RADIATION BIOLOGY AND SPACE R$2,465,718
· FY2008 · National Aeronautics and Space Administration
THE PRIMARY RISK FACTOR LIMITING THE AMOUNT OF TIME AN ASTRONAUT CAN SPEND IN FLIGHT IS THE RISK OF CANCER INDUCTION RESULTING FROM THE UNIQUE RADIATIONS INHERENT TO THE DEEP SPACE ENVIRONMENT. ONE STRATEGY FOR MITIGATING RADIATION INDUCED CARCINOGENESIS IS TO PROVIDE BIOLOGICAL COUNTERMEASURES THAT MITIGATE RADIATION INJURY AND CANCER INDUCTION. TO DATE THE ONLY FDA APPROVED RADIOPROTECTOR IS THE FREE RADICAL SCAVENGER AMIFOSTINE; HOWEVER CONCERNS ABOUT TOXICITY AND REPORTS OF SEVERE ANAPHYLACTIC REACTIONS TO THIS DRUG PREVENT ITS USE IN SPACEFLIGHT. THEREFORE THERE IS A NEED TO DETERMINE AND VALIDATE APPROPRIATE BIOLOGICAL COUNTERMEASURES TO MITIGATE SPACE RADIATION CARCINOGENESIS THEREBY INCREASING THE AMOUNT OF TIME ASTRONAUTS CAN SAFELY SPEND IN SPACE. IN THE PROPOSED STUDIES WE WILL EVALUATE THE RADIO PROTECTIVE POTENTIAL OF GC4419 A NOVEL SUPEROXIDE DISMUTASE MIMETIC DEVELOPED BY GALERA THERAPUTICS (ST. LOUIS MO) IN MITIGATING SPACE RADIATION CARCINOGENESIS. DUE TO ITS EFFICACY IN PHASE 1 CLINICAL TRIALS AND PRE-CLINICAL DATA GENERATED BY OUR GROUP GC4419 IS CURRENTLY BEING FAST TRACKED INTO FDA PHASE II HUMAN CLINICAL TRIALS AS A RADIOPROTECTOR FOR PATIENTS UNDERGOING CHEMORADIATION THERAPY FOR THE TREATMENT OF HEAD AND NECK CANCER. NOT ONLY DOES GC4419 REDUCE THE FREQUENCY OF RADIATION INDUCED ADVERSE EFFECTS PRE-CLINICAL DATA SUGGEST IT HAS POTENT ANTI-CARCINOGENIC AND ANTI-TUMOR EFFECTS AS WELL. THEREFORE GC4419 REPRESENTS A SAFE CLINICALLY TESTED COUNTERMEASURE TO REDUCE RADIATION INJURY. IN THE PROPOSED STUDIES WE WILL EVALUATE THE EFFICACY OF GC4419 IN PREVENTING SPACE RADIATION INDUCED CARCINOGENESIS FOCUSING SPECIFICALLY ON THE LUNG AS A PRIMARY TUMOR SITE.$2,461,498
· FY2020 · National Aeronautics and Space Administration
FAMILIAL HYPERCHOLESTEROLEMIA IN THE UNITED STATES: EVALUATING A CENTRALIZED CASCADE SCREENING MODEL TO IMPROVE EARLY DIAGNOSIS$2,016,389
· FY2021 · Defense Health Agency
DEVELOPMENT OF NON-INVASIVE IMAGING PROBES FOR ASSESSING ALTERED MITOCHONDRIAL METABOLISM OF NON-ALCOHOLIC FATTY LIVER DISEASE$1,978,071
· FY2022 · Defense Health Agency
HIPPO SIGNALING IN POLYCYSTIC KIDNEY DISEASE$1,943,391
· FY2020 · Defense Health Agency
URINARY MAGNESIUM REGULATION BY MUSIN-1 AND UROMODULIN-AN UNEXPECTED ROLE IN THE DEVELOPMENT OF TYPE 2 DIABETES MELLITUS$1,943,088
· FY2019 · Defense Health Agency
MECHANISM OF ACTION OF ANTI-MIR-17 HUMAN DRUG CANDIDATE$1,931,764
· FY2018 · Department of the Army
NANOTECHNOLOGY IN CELLULAR THERAPIES$1,900,000
· FY2009 · Department of the Army
A WITHIN-SCAR, RANDOMIZED CONTROL TRIAL COMPARING FRACTIONAL ABLATIVE CARBON DIOXIDE LASER TO NON-ENERGY-BASED, MECHANICAL TISSUE EXTRACTION AND NO T$1,749,178
· FY2018 · Defense Health Agency
UNCOVERING AND TREATING THE BRAIN-TO-BONE AND BONE-TO-BRAIN AXIS AFTER TRAUMATIC BRAIN INJURY$1,640,000
· FY2025 · Defense Health Agency
THERAPEUTIC PARAMETERS AND MECHANISM OF ACTION OF ANTI-MIR-17 DRUGS IN ADPKD$1,640,000
· FY2025 · Defense Health Agency
REPURPOSING MEK-INHIBITORS FOR LYMPHATIC MALFORMATIONS$1,639,308
· FY2021 · Defense Health Agency